BRAIN and NERVE－神経研究の進歩69巻7号

2017年07月発行

増大特集 あしたのアルツハイマー病治療

今日の国際共同研究における臨床評価尺度と認知機能検査

著者： 井原涼子¹

所属機関： ¹東京大学医学部附属病院 早期・探索開発推進室

ページ範囲：P.781 - P.787

文献概要

アルツハイマー病の臨床研究では，臨床症状と認知機能障害を定量化して重症度を記載するため，臨床評価尺度と認知機能検査が用いられる。近年，プレクリニカル期アルツハイマー病や軽度認知障害を対象とした研究が増え，使用されるスケールも変化している。国際共同研究では難易度を等しく保ちながら翻訳し，標準化を行う過程が必要である。また，多施設共同研究では手順の画一化を図り，質の高いデータを得る工夫も重要である。

参考文献

1)U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Guidance for Industry - Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease. Draft Guidance. 2013　http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryInformation/cuidances/ucm338287.pdf［2017年4月26日閲覧］

2)Kozauer N, Katz R: Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 368: 1169-1171, 2013

3)Morris JC: The clinical dementia rating (CDR): current version and scoring rules. Neurology 43: 2412-2414, 1993

4)Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, et al: The AD8: a brief informant interview to detect dementia. Neurology 65: 559-564, 2005

5)Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S: Measurement of functional activities in older adults in the community. J Gerontol 37: 323-329, 1982

6)Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, et al: The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314, 1994

7)Sheikh JI, Yesavage JA: Geriatric depression scale (GDS): recent evidence and development of a shorter version. Brink TL(ed): Clinical Gerontology: a guide to assessment and intervention (with instructor's manual). Haworth Press, New York, 1986, pp165-173

8)Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198, 1975

9)Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, et al: The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53: 695-699, 2005

10)Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364, 1984

11)Wechsler D: Wechsler Memory Scale-Revised. The Psychological Corporation, San Antonio, 1987

12)Grober E, Buschke H, Crystal H, Bang S, Dresner R: Screening for dementia by memory testing. Neurology 38: 900-903, 1998

13)Kaplan E, Goodglass H, Weintraub S: The Boston Naming Test. Lea ＆ Febiger, Philadelphia, 1983

14)Gollan TH, Weissberger GH, Runnqvist E, Montoya RI, Cera CM: Self-ratings of spoken language dominance: a multilingual naming test (MINT) and preliminary norms for young and aging Spanish-English bilinguals. Biling (Camb Engl) 15: 594-615, 2012

15)Reitan RM: Validity of the TrailMaking Test as an indicator of organic brain damage. Percept Mot Skills 8: 271-276, 1958

16)Wechsler D: Wechsler Adult Intelligence Scale®- Third Edition (WAIS®-III). Pearson, San Antonio, 1997

17)Goodglass H, Kaplan E: The Assessment of Aphasia and Related Disorders. Lea ＆ Febiger, Philadelphia, 1983

18)Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, et al: The preclinical Alzheimer cognitive composite:measuring amyloid-related decline. JAMA Neurol 71: 961-970, 2014

19)Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, et al: A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64: 1323-1329, 2007

20)Lim YY, Ellis KA, Harrington K, Ames D, Martins RN, et al: Use of the CogState brief battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Clin Exp Neuropsychol 34: 345-358, 2012